![Rupert Vessey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Rupert Vessey
Director/Board Member at
BIO-TECHNE CORPORATION
Net worth: 607 801 $ as of 2026-04-29
Profile
Rupert J. Vessey holds the position of Executive VP-Research & Early Development at Bristol Myers Squibb Co. He is also on the board of Bio-Techne Corp., PharmAkea, Inc., Sidecar Therapeutics, Inc. and Elstar Therapeutics, Inc. and Member of The Royal College of Physicians. In the past Rupert J. Vessey held the position of Senior VP-Early Development & Discovery Sciences at Merck & Co., Inc. and President-Research & Early Development at Celgene Corp. Dr. Vessey received a graduate degree, a doctorate and an undergraduate degree from the University of Oxford.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-10-29 | 10,987 ( 0.01% ) | 607 801 $ | 2026-04-29 | |
| 2026-02-26 | 0 ( -.--% ) | - $ | 2026-04-29 |
Rupert Vessey active positions
| Companies | Position | Start |
|---|---|---|
| BIO-TECHNE CORPORATION | Director/Board Member | 2019-06-25 |
| GENERATE BIOMEDICINES, INC. | Director/Board Member | 2024-05-31 |
PharmAkea, Inc.
 PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drug candidates against protein targets involved in fibroproliferative diseases | Director/Board Member | - |
Sidecar Therapeutics, Inc.
 Sidecar Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Director/Board Member | - |
Marengo Therapeutics, Inc.
 Marengo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunotherapies | Director/Board Member | 2018-07-31 |
The Royal College of Physicians
 The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Nereid Therapeutics, Inc.
 Nereid Therapeutics, Inc. BiotechnologyHealth Technology Operates as a bio-molecular condensate drug discovery and development company | Director/Board Member | 2021-10-24 |
Flagship Pioneering, Inc.
 Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Private Equity Investor | 2023-06-30 |
Former positions of Rupert Vessey
| Companies | Position | End |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Chief Tech/Sci/R&D Officer | 2023-07-02 |
| ░░░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - |
Training of Rupert Vessey
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
53
1st degree connections
14
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 14 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Bio-Techne Corp.
 Bio-Techne Corp. BiotechnologyHealth Technology Manufactures and sells biological products | Health Technology |
PharmAkea, Inc.
PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drug candidates against protein targets involved in fibroproliferative diseases | Health Technology |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Flagship Pioneering, Inc.
Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Finance |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
The Royal College of Physicians
The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company to treat cancer, HIV and cardiovascular diseases | Health Technology |
Sidecar Therapeutics, Inc.
Sidecar Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Marengo Therapeutics, Inc.
Marengo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunotherapies | Health Technology |
Nereid Therapeutics, Inc.
Nereid Therapeutics, Inc. BiotechnologyHealth Technology Operates as a bio-molecular condensate drug discovery and development company | Health Technology |
Generate Biomedicines, Inc.
 Generate Biomedicines, Inc. BiotechnologyHealth Technology Operates as a clinical-stage generative biology company that provides biotechnology and drug design & development services | Health Technology |
- Stock Market
- Insiders
- Rupert Vessey
